Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index; 53 of the 249 sources its claims cite were checked for support.

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines

Open access

Abstract

Context: Insulin resistance is common in women with polycystic ovary syndrome (PCOS). Inositol may have insulin sensitizing effects; however, its efficacy in the management of PCOS remains indeterminate. Objective: To inform the 2023 international evidence-based guidelines in PCOS, this systematic review and meta-analysis evaluated the efficacy of inositol, alone or in combination with other therapies, in the management of PCOS. Data Sources: Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 2022. Study Selection: Thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses were included. Data Extraction: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. Data Synthesis: Thirteen comparisons were assessed, with 3 in meta-analyses. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes, and the evidence is very uncertain for body mass indexI. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited. Conclusion: The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis found limited and inconclusive evidence that inositol improves PCOS outcomes, with some low-certainty metabolic/hormonal benefits for DCI or MI plus folic acid. Metformin was superior to MI for waist-hip ratio and hirsutism, while MI caused fewer gastrointestinal adverse events.

Key findings

  • Across 30 RCTs (n = 2230; 1093 intervention, 1137 control), 19 studies contributed to meta-analyses; most outcomes were low to very low certainty.
  • DCI vs placebo showed low-certainty benefits for free testosterone (MD −0.46), SHBG (MD 1.79), DHEAS (MD −139.43), AUC insulin (MD −3.65), AUC glucose (MD −20.85), triglycerides (MD −31.95), and ovulation (OR 11.50), but placebo was superior for BMI (MD 0.67).
  • MI + FA vs FA showed very-low-certainty improvements in fasting insulin (MD −4.17) and HOMA-IR (MD −1.24), with no differences in BMI, clinical pregnancy rate, positive hCG, or ovulation rate.
  • MI vs metformin: metformin was superior for FG score (MD 2.42) and WHR (MD 0.04); MI was superior for SHBG (MD 3.85) and GI adverse events (OR 0.09), with no differences in reproductive outcomes.

Methods

  • Systematic review and meta-analysis following PRISMA, prospectively registered with PROSPERO (CRD 42022356057), to inform the 2023 International Evidence-based PCOS Guideline.
  • Searched Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 5, 2022; included RCTs of females with PCOS diagnosed by Rotterdam, NIH, or AEPCOS criteria, comparing inositol alone or combined with other therapies.
  • Data extracted by one reviewer and verified by a second; risk of bias assessed with Cochrane Risk of Bias 1.0, certainty with GRADE, and trial integrity with the RIGID framework; random-effects meta-analyses used where possible.

Limitations

  • The paper states it included only English-language studies, did not search grey literature, found generally high risk of bias, and had small sample sizes/study numbers that precluded some meta-analyses and lowered certainty.
  • The paper states adverse events were not reported by the majority of studies (23/29), and only one study examined adolescents, limiting comparisons in that subgroup.
  • The text also makes evident that planned subgroup analyses for menopausal stage, adolescents/adults, and BMI category were not conducted due to the small number of trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgad762

Cites

62 of 63 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. PRISMA flowchart of study selection. Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 1. PRISMA flowchart of study selection. Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.CC BY · PubMed Central
Figure 2. Risk of bias summary and graph.
Figure 2. Risk of bias summary and graph.CC BY · PubMed Central
Figure 3. D-chiro-inositol vs placebo forest plots.
Figure 3. D-chiro-inositol vs placebo forest plots.CC BY · PubMed Central
Figure 4. Myo-inositol + folic acid vs folic acid forest plots.
Figure 4. Myo-inositol + folic acid vs folic acid forest plots.CC BY · PubMed Central
Figure 5. Myo-inositol vs metformin forest plots.
Figure 5. Myo-inositol vs metformin forest plots.CC BY · PubMed Central

Verification

Claims the paper makes

34 Valid · 5 Not valid · 66 Not checked · 90 Own results and interpretations

90 more claims · 17 with their cited sources checked

Create a free account to see all 195 claims and to verify the 26 references still open.

See all claims — free account
  • Probably not a substantial claim. 67
  • It may state two separate claims as one. 50
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 64 references

Research works printed but not linked: 4

  1. Teede, 10.26180/24003834.v1.2023 · doi:10.26180/24003834.v1.2023
  2. Schumemann, 2013, GRADE handbook for Grading of Recommendations Assessment, Development and Evaluation
  3. Nehra, 2017, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women, Int J Pharm Sci Res, 8, 1664
  4. Fu, 2015, AHRQ Methods for Effective Health Care. Change Score or Followup Score? An Empirical Evaluation of the Impact of Choice of Mean Difference Estimates

Cited by

See all 70

Metadata

Authors
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C.
Affiliations
  • Massachusetts General Hospital (US)
  • University of Wolverhampton (GB)
  • Western Sydney University (AU)
  • University of Southampton (GB)
  • University of Pittsburgh (US)
  • Discipline of Paediatrics, The University of Adelaide and Robinson Research Institute , Adelaide 5005 , Australia
  • Universidade Federal do Rio Grande do Sul (BR)
  • Peking University Third Hospital (CN)
  • Monash University (AU)
  • Flinders University (AU)
Corresponding author
Ee, Carolyn
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2024-01-02
Volume
109
Issue
6
Pages
1630-1655
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4390508316
Cited by
70
References
64
Citations by year
2026: 35 · 2025: 29 · 2024: 6
FWCI
2.81
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
Funders
  • Australian National Health and Medical Research Council
  • NHMRC
  • Centre for Research Excellence in Women’s Health in Reproductive Life
  • CRE WHIRL
  • NHMRC CRE WHIRL
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, insulin sensitization, metformin, ovulation, hirsutism, body mass index, waist-to-hip ratio, gastrointestinal adverse effects, shared decision-making
MeSH terms
Female, Humans, Inositol, Insulin Resistance, Polycystic Ovary Syndrome, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. https://app.cochat.ai/papers/10.1210/clinem/dgad762
The paper
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.